Loading
companiesCompany
Velsera (Seven Bridges and Pierian)
Genomics cloud and clinical interpretation company formed from Seven Bridges, Pierian, and UgenTec in 2023; operates the NCI Cancer Genomics Cloud.
Overview
Velsera, based in Boston, is a genomics cloud and clinical interpretation company formed in 2023 from Seven Bridges, Pierian and UgenTec, and it operates the NCI Cancer Genomics Cloud. It provides a bioinformatics platform for research and for clinical next-generation sequencing reporting. OnCo links it to clinical NGS bioinformatics and variant interpretation and to genomics cloud and secure research environments. Whether a merged research and clinical platform serves either market as well as the specialists did is the open question. The genomics cloud technology page carries the wider picture.
Similar pages
- CompanyDNAnexus
Shares Genomics cloud and secure research environments and the tag supporting.
- CompanySOPHiA GENETICS
Shares Clinical NGS bioinformatics and variant interpretation and the tag supporting.
- CompanyQIAGEN
Shares Clinical NGS bioinformatics and variant interpretation and the tag supporting.
- TechnologyCancer variant knowledgebases and molecular tumour boards
Shares Clinical NGS bioinformatics and variant interpretation and the tag supporting.
- TechnologyOncology EHR and real-world data platforms
Shares Genomics cloud and secure research environments and the tag supporting.
Software in use
The software of oncology →Commercial and regulated products that this organisation sells. Each card says what is behind it: a regulator's database, the literature, a public body's list, or only the company's own words. Listing is not endorsement, and a clearance is a regulatory fact, not a clinical one.
A case management and sign-out environment for molecular pathology, tracking a tumour case from sequencing run to signed report.
Velsera (Seven Bridges and Pierian)Paper 2020